# Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection

> **NCT04042740** · PHASE2 · COMPLETED · sponsor: **Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections** · enrollment: 45 (actual)

## Conditions studied

- Hepatitis C Infection
- HIV Infection

## Interventions

- **DRUG:** Glecaprevir/Pibrentasvir (G/P)

## Key facts

- **NCT ID:** NCT04042740
- **Lead sponsor:** Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-20
- **Primary completion:** 2023-05-18
- **Final completion:** 2023-08-22
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2024-07-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04042740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04042740, "Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04042740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*